Sanderson Jean, Martyn-St James Marrissa, Stevens John, Goka Edward, Wong Ruth, Campbell Fiona, Selby Peter, Gittoes Neil, Davis Sarah
Health Economics and Decision Science, School of Health and Related Research, University of Sheffield, Regent Court, 30 Regent Street, Sheffield, S1 4DA, United Kingdom.
Department of Medicine, Manchester Royal Infirmary, Oxford Road, Manchester, M13 9WL, United Kingdom.
Bone. 2016 Aug;89:52-58. doi: 10.1016/j.bone.2016.05.013. Epub 2016 Jun 1.
To assess the relative efficacy of bisphosphonates (alendronate, risedronate, ibandronate and zoledronic acid) for the treatment of osteoporosis using network meta-analysis (NMA).
A systematic review of the literature was conducted using PRISMA guidelines. A network meta-analysis was used to determine the relative efficacy of treatments on four fracture outcomes (vertebral, non-vertebral, hip and wrist) and percentage change in femoral neck bone mineral density (BMD). Treatment effects were modelled using an exchangeable treatment effects model. Heterogeneity in treatment effects was explored by considering potential treatment effect modifiers using meta-regression. Where appropriate, inconsistency between direct and indirect evidence was assessed using node-splitting.
46 randomised controlled trials (RCTs) were identified. Twenty seven RCTs provided fracture data and 35 RCTs provided BMD data for analysis. Zoledronic acid was associated with the greatest treatment effect on vertebral fractures (HR 0.41, 95% CrI: 0.28, 0.56) and percentage change in BMD (3.21, 95%: CrI 2.52, 3.86) compared to placebo. The greatest treatment effect on non-vertebral and wrist fractures was given by risedronate (HR 0.72, 95%: CrI 0.53, 0.89 and HR 0.77, 95%: CrI 0.44, 1.24, respectively). For hip fractures the greatest treatment effect was given by alendronate (HR 0.78, 95% CrI: 0.44, 1.30).
All treatments examined were associated with beneficial effects on fractures and femoral neck BMD relative to placebo. For vertebral fractures and percentage change in femoral neck BMD the treatment effects were statistically significant for all treatments. Pairwise comparisons between treatments indicated that no active treatment was statistically significantly more effective than any other active treatment for fracture outcomes. There was some heterogeneity in treatment effects between studies suggesting differential treatment effects according to study characteristics; however, there was no evidence of differential treatment effects with respect to gender and age.
采用网状Meta分析(NMA)评估双膦酸盐类药物(阿仑膦酸钠、利塞膦酸钠、伊班膦酸钠和唑来膦酸)治疗骨质疏松症的相对疗效。
按照PRISMA指南对文献进行系统评价。采用网状Meta分析确定各治疗方法对四种骨折结局(椎体骨折、非椎体骨折、髋部骨折和腕部骨折)以及股骨颈骨密度(BMD)百分比变化的相对疗效。使用可交换治疗效应模型对治疗效果进行建模。通过使用Meta回归考虑潜在的治疗效应修饰因素来探索治疗效应的异质性。在适当的情况下,使用节点拆分评估直接证据和间接证据之间的不一致性。
共纳入46项随机对照试验(RCT)。27项RCT提供了骨折数据,35项RCT提供了BMD数据用于分析。与安慰剂相比,唑来膦酸对椎体骨折(风险比HR 0.41,95%可信区间CrI:0.28,0.56)和BMD百分比变化(3.21,95%:CrI 2.52,3.86)的治疗效果最佳。利塞膦酸钠对非椎体骨折和腕部骨折的治疗效果最佳(HR分别为0.72,95%:CrI 0.53,0.89和HR 0.77,95%:CrI 0.44,1.24)。对于髋部骨折,阿仑膦酸钠的治疗效果最佳(HR 0.78,95% CrI:0.44,1.30)。
与安慰剂相比,所有研究的治疗方法对骨折和股骨颈BMD均有有益影响。对于椎体骨折和股骨颈BMD百分比变化,所有治疗方法的治疗效果均具有统计学意义。各治疗方法之间的成对比较表明,对于骨折结局,没有一种活性治疗方法在统计学上比任何其他活性治疗方法更有效。研究之间的治疗效果存在一定异质性,提示根据研究特征治疗效果存在差异;然而,没有证据表明在性别和年龄方面治疗效果存在差异。